跳至主要内容
临床试验/EUCTR2019-003855-12-ES
EUCTR2019-003855-12-ES进行中(未招募)1 期

Phase III Clinical Trial, single-center, randomized, double-blind, to demonstrate a lower incidence of acute diaphragmatic paralysis of the brachial plexus block with interscalene approach in arthroscopic shoulder surgery after administration of 25 mg of 0.25% Levobupivacaine compared to 50 mg administration

Fundación Instituto de Investigación Sanitaria Aragón0 个研究点目标入组 48 人开始时间: 2019年12月2日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1. Written informed consent to participate in the clinical trial.
  • 2. Be intervened with scheduled arthroscopic shoulder surgery.
  • 3. Age between 18 and 80 years old,
  • 4. ASA I-III.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 8

排除标准

  • 1. Allergic to local amide type anesthetics, opioids or nonsteroidal anti-inflammatory drugs.
  • 2. Non-acceptance for the realization of the BBPAI.
  • 3. Contraindication for the realization of the BPBAI,
  • 4. Contraindication for performing a spirometry.
  • 5. History of pulmonary pathology: moderate or severe COPD, or unstable asthma.
  • 6. Previous diaphragmatic paralysis or other neuromuscular pathology with respiratory involvement,
  • 7. Pregnancy
  • 8. Coagulation disorders (INR> 3, TTPA> 35 and AP <50%).
  • 9. Brachial plexus neuropathy.
  • 10. Chronic opioid consumption: defined as the administration of opioids for more than 3 months or equivalent to more than 5 mg daily of VO Morphine for 1 month.

研究者

相似试验